Daniel E. Spratt, MD, on Prostate Cancer: Relugolix vs Leuprolide

October 28, 2020 By The ASCO Post Staff

Daniel E. Spratt, MD, of the University of Michigan Rogel Cancer Center, discusses phase III results of the HERO trial, which suggested benefits of the oral medication relugolix: a substantially faster time to castration with longer duration, fewer cardiac events, and a faster return to normal testosterone levels compared with leuroplide (Abstract 35).

Related Content